Ligand Pharmaceuticals INC Form 4 insider transactions

Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals Inc, sold 31,641 shares of common stock on August 12, 2026 for $292.06 per share.

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals Inc, sold 5,000 shares of common stock on August 3, 2026.

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals Inc., reported transactions involving common stock and employee stock options.

Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals Inc., acquired 17 shares of common stock through the company's Employee Stock Purchase Plan.

Todd C. Davis, CEO and Director of Ligand Pharmaceuticals, acquired 132 shares of common stock through the Ligand Employee Stock Purchase Plan.

Stephen L. Sabba, a Director at Ligand Pharmaceuticals Inc., reported transactions involving common stock and stock options on June 16, 2026.

Director Jason Haas exercised stock options and sold shares of Ligand Pharmaceuticals Inc. on June 12, 2026.

Director Jason Aryeh reported a series of stock acquisitions and sales, alongside a reallocation of holdings in Ligand Pharmaceuticals.

Director John L. LaMattina sold 4,591 shares of Ligand Pharmaceuticals common stock on June 10, 2026.

Ligand Pharmaceuticals director Martine Zimmermann was granted restricted stock units and stock options following the company's annual meeting.

Director Stephen L. Sabba received an equity grant of restricted stock units and stock options from Ligand Pharmaceuticals.

Ligand Pharmaceuticals director John L. LaMattina was granted 836 restricted stock units and 2,938 stock options as part of an annual board compensation package.

Ligand Pharmaceuticals Director John W. Kozarich was granted 836 restricted stock units and 2,938 stock options following the company's annual meeting.

Ligand Pharmaceuticals director Jason Haas was granted 836 restricted stock units and 2,938 stock options as part of an annual board compensation package.

Director Nancy Ryan Gray was granted 836 restricted stock units and 2,938 stock options as part of an annual board compensation package.

Ligand Pharmaceuticals Chief Legal Officer Andrew Reardon exercised options and sold 5,000 shares of common stock.

Ligand Pharmaceuticals CFO Octavio Espinoza exercised stock options for 1,736 shares of common stock on May 27, 2026.

Director John W. Kozarich exercised stock options and sold shares of Ligand Pharmaceuticals under a 10b5-1 trading plan.

Ligand Pharmaceuticals Chief Legal Officer Andrew Reardon exercised 5,000 stock options and sold the resulting shares under a Rule 10b5-1 trading plan.

Ligand Pharmaceuticals Director John W. Kozarich reported the sale of common stock valued at over $100,000 through a pre-arranged trading plan.

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals Inc., reported transactions involving the acquisition of stock options and the sale of common stock on April 1, 2026, under a Rule 10b5-1 trading plan.

A director at Ligand Pharmaceuticals exercised stock options and subsequently sold an equal number of shares under a pre-arranged trading plan.

Ligand Pharmaceuticals CFO Octavio Espinoza received significant equity awards, including restricted stock units and stock options, on March 2, 2026.

Ligand Pharmaceuticals CEO Todd C. Davis acquired 10,495 restricted stock units and 50,058 employee stock options, signaling increased insider ownership.

Ligand Pharmaceuticals' Chief Legal Officer and Secretary, Andrew Reardon, was granted 4,513 restricted stock units and 21,525 employee stock options.

Ligand Pharmaceuticals Director Stephen L. Sabba sold 1,000 shares of common stock for an average price of $207.87 per share under a pre-arranged trading plan.

Ligand Pharmaceuticals CFO Octavio Espinoza reported the exercise of stock options and subsequent sale of common stock under a pre-arranged trading plan.

Ligand Pharmaceuticals' Chief Legal Officer, Andrew Reardon, exercised stock options and subsequently sold a portion of common stock under a pre-arranged 10b5-1 trading plan.

Ligand Pharmaceuticals CFO Octavio Espinoza exercised stock options and subsequently sold a significant number of common shares under a pre-arranged 10b5-1 trading plan.

Ligand Pharmaceuticals Director Stephen L. Sabba exercised stock options and immediately sold the acquired shares on March 3, 2026.